Ciric To

2.3k total citations
21 papers, 1.2k citations indexed

About

Ciric To is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ciric To has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Ciric To's work include Cancer therapeutics and mechanisms (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Quinazolinone synthesis and applications (4 papers). Ciric To is often cited by papers focused on Cancer therapeutics and mechanisms (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Quinazolinone synthesis and applications (4 papers). Ciric To collaborates with scholars based in United States, South Korea and Canada. Ciric To's co-authors include Charles C. Brinton, Richard E. Isaacson, Harley W. Moon, Pasi A. Jänne, Mierzhati Mushajiang, Nathanael S. Gray, Jaebong Jang, Michael J. Eck, Dries J.H. De Clercq and Bo Hee Shin and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Ciric To

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ciric To United States	14	652	408	394	174	143	21	1.2k
Աննա Մարտիրոսյան France	18	561 0.9×	319 0.8×	129 0.3×	138 0.8×	79 0.6×	24	1.7k
Richard W. Birkinshaw Australia	21	864 1.3×	436 1.1×	62 0.2×	94 0.5×	54 0.4×	34	3.1k
Steve L. Martin United Kingdom	13	375 0.6×	75 0.2×	110 0.3×	53 0.3×	170 1.2×	20	1.0k
Juliano D. Paccez Brazil	19	419 0.6×	208 0.5×	73 0.2×	38 0.2×	45 0.3×	46	1.0k
Jean‐François Haeuw France	21	944 1.4×	289 0.7×	70 0.2×	73 0.4×	84 0.6×	35	1.8k
Rafael Molina Spain	21	1.0k 1.5×	311 0.8×	73 0.2×	28 0.2×	66 0.5×	71	1.6k
Andrei A. Purmal United States	25	1.4k 2.1×	270 0.7×	141 0.4×	21 0.1×	90 0.6×	57	2.0k
Stanley A. Hefta United States	22	1.1k 1.8×	207 0.5×	42 0.1×	58 0.3×	57 0.4×	33	2.0k
Jeffrey Hill Singapore	25	1.0k 1.6×	247 0.6×	75 0.2×	18 0.1×	172 1.2×	65	1.8k
Ivan King United States	18	386 0.6×	203 0.5×	115 0.3×	45 0.3×	97 0.7×	39	1.6k

Countries citing papers authored by Ciric To

Since Specialization

Citations

This map shows the geographic impact of Ciric To's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ciric To with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ciric To more than expected).

Fields of papers citing papers by Ciric To

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ciric To. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ciric To. The network helps show where Ciric To may publish in the future.

Co-authorship network of co-authors of Ciric To

This figure shows the co-authorship network connecting the top 25 collaborators of Ciric To. A scholar is included among the top collaborators of Ciric To based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ciric To. Ciric To is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Li, Zhengnian, Jie Jiang, Scott B. Ficarro, et al.. (2024). Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality. ACS Central Science. 10(6). 1156–1166. 5 indexed citations

2.

Heppner, David E., et al.. (2023). A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology. Molecular Pharmacology. 105(2). 97–103.

3.

Beyett, Tyler S., Ciric To, David E. Heppner, et al.. (2023). Development of Mutant-Selective Allosteric EGFR Inhibitors for Drug-Resistant Lung Cancer. Journal of Pharmacology and Experimental Therapeutics. 385. 517–517.

4.

Beyett, Tyler S., Ciric To, David E. Heppner, et al.. (2022). Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature Communications. 13(1). 2530–2530. 56 indexed citations

5.

Gero, Thomas W., David E. Heppner, Tyler S. Beyett, et al.. (2022). Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorganic & Medicinal Chemistry Letters. 68. 128718–128718. 13 indexed citations

6.

Heppner, David E., Ciric To, Marcel Günther, et al.. (2021). Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. Journal of Medicinal Chemistry. 65(2). 1370–1383. 26 indexed citations

7.

Jang, Jaebong, Ciric To, Dries J.H. De Clercq, et al.. (2020). Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. Angewandte Chemie. 132(34). 14589–14597. 13 indexed citations

8.

Jang, Jaebong, Ciric To, Dries J.H. De Clercq, et al.. (2020). Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. Angewandte Chemie International Edition. 59(34). 14481–14489. 108 indexed citations

9.

To, Ciric, Jaebong Jang, Ting Chen, et al.. (2019). Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discovery. 9(7). 926–943. 250 indexed citations

10.

Rangachari, Deepa, Ciric To, Paul A. VanderLaan, et al.. (2019). EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Journal of Thoracic Oncology. 14(11). 1995–2002. 69 indexed citations

11.

Clercq, Dries J.H. De, David E. Heppner, Ciric To, et al.. (2019). Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. ACS Medicinal Chemistry Letters. 10(11). 1549–1553. 65 indexed citations

12.

Jang, Jaebong, Ciric To, Magda Bahcall, et al.. (2017). Discovery of a potent dual ALK and EGFR T790M inhibitor. European Journal of Medicinal Chemistry. 136. 497–510. 42 indexed citations

13.

To, Ciric, Ashbeel Roy, Eddie Chan, Marco A. M. Prado, & Gianni M. Di Guglielmo. (2017). Synthetic triterpenoids inhibit GSK3β activity and localization and affect focal adhesions and cell migration. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1864(7). 1274–1284. 9 indexed citations

14.

To, Ciric, Carol S. Ringelberg, Darlene B. Royce, et al.. (2015). Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. 36(7). 769–781. 60 indexed citations

15.

To, Ciric, Eun‐Hee Kim, Darlene B. Royce, et al.. (2014). The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice. Cancer Prevention Research. 7(7). 698–707. 60 indexed citations

16.

To, Ciric, et al.. (2014). Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model. Cancer Research. 74(19_Supplement). 2965–2965. 1 indexed citations

17.

To, Ciric, Brian H. Shilton, & Gianni M. Di Guglielmo. (2010). Synthetic Triterpenoids Target the Arp2/3 Complex and Inhibit Branched Actin Polymerization. Journal of Biological Chemistry. 285(36). 27944–27957. 39 indexed citations

18.

To, Ciric, Sarang Kulkarni, Tony Pawson, et al.. (2008). The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor β-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex. Journal of Biological Chemistry. 283(17). 11700–11713. 28 indexed citations

19.

Morgan, Rebecca L., Richard E. Isaacson, Harley W. Moon, Charles C. Brinton, & Ciric To. (1978). Immunization of suckling pigs against enterotoxigenic Escherichia coli-induced diarrheal disease by vaccinating dams with purified 987 or K99 pili: protection correlates with pilus homology of vaccine and challenge. Infection and Immunity. 22(3). 771–777. 142 indexed citations

20.

To, Ciric, et al.. (1977). Isolation and characterization of Escherichia coli phase variants and mutants deficient in type 1 pilus production. Journal of Bacteriology. 130(1). 495–505. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact